CompletedPhase 2NCT05186051
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)
Studying NLRP3-associated autoinflammatory disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zydus Lifesciences Limited
- Principal Investigator
- Dr Deven Parmar, MDCadila Healthcare Ltd.
- Intervention
- ZYIL1 capsule(drug)
- Enrollment
- 3 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2022 – 2022
Study locations (1)
- Department of Clinical Immunology and Allergy, Adelaide, Australia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05186051 on ClinicalTrials.govOther trials for NLRP3-associated autoinflammatory disease
Additional recruiting or active studies for the same condition.
See all trials for NLRP3-associated autoinflammatory disease →